These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 9499841)

  • 21. Pneumococcal susceptibility to meropenem in a mid-south children's hospital.
    Buckingham SC; Davis Y; English BK
    South Med J; 2002 Nov; 95(11):1293-6. PubMed ID: 12539996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the appropriate use of meropenem for the treatment of serious bacterial infections.
    Kollef MH
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S1-2. PubMed ID: 18713044
    [No Abstract]   [Full Text] [Related]  

  • 23. [Not to forget interaction between meropenem and valproic acid].
    Berardi D; Clemente R; Finn BC; Bruetman JE; Young P
    Rev Med Chil; 2014 Mar; 142(3):400-1. PubMed ID: 25052282
    [No Abstract]   [Full Text] [Related]  

  • 24. Imipenem.
    Salaria M
    Indian Pediatr; 2001 Dec; 38(12):1370-3. PubMed ID: 11752734
    [No Abstract]   [Full Text] [Related]  

  • 25. [Meropenem: new clinical results].
    Minerva Chir; 1995 Apr; 50(4):x-xi. PubMed ID: 7675276
    [No Abstract]   [Full Text] [Related]  

  • 26. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing.
    Tam VH; Ledesma KR; Schilling AN; Lim TP; Yuan Z; Ghose R; Lewis RE
    Diagn Microbiol Infect Dis; 2009 Aug; 64(4):427-33. PubMed ID: 19631096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit.
    Toltzis P; Dul M; O'Riordan MA; Melnick D; Lo M; Blumer J
    Pediatr Crit Care Med; 2009 Jan; 10(1):49-54. PubMed ID: 19057450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbapenems: a potent class of antibiotics.
    Nicolau DP
    Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thermal and alkaline stability of meropenem: degradation products and cytotoxicity.
    Mendez A; Chagastelles P; Palma E; Nardi N; Schapoval E
    Int J Pharm; 2008 Feb; 350(1-2):95-102. PubMed ID: 17904314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.
    Horiuchi M; Kimura M; Tokumura M; Hasebe N; Arai T; Abe K
    Toxicology; 2006 May; 222(1-2):114-24. PubMed ID: 16549226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meropenem-clavulanate: a new strategy for the treatment of tuberculosis?
    Holzgrabe U
    ChemMedChem; 2009 Jul; 4(7):1051-3. PubMed ID: 19462395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
    Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S
    Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute seizures due to a probable interaction between valproic acid and meropenem.
    Coves-Orts FJ; Borrás-Blasco J; Navarro-Ruiz A; Murcia-López A; Palacios-Ortega F
    Ann Pharmacother; 2005 Mar; 39(3):533-7. PubMed ID: 15701769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel IMP-1 metallo-beta-lactamase inhibitors can reverse meropenem resistance in Escherichia coli expressing IMP-1.
    Moloughney JG; D Thomas J; Toney JH
    FEMS Microbiol Lett; 2005 Feb; 243(1):65-71. PubMed ID: 15668002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex beta-lactamase patterns including extended-spectrum enzymes.
    Segatore B; Setacci D; Perilli M; Franchino L; Franceschini N; Agnifili A; Rossolini GM; Amicosante G
    Int J Antimicrob Agents; 2004 May; 23(5):480-6. PubMed ID: 15120727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Meropenem (Meronem). Guides for intravenous use of meropenem (information for specialists)].
    Antibiot Khimioter; 1998; 43(1):46-8. PubMed ID: 9532332
    [No Abstract]   [Full Text] [Related]  

  • 39. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.